Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 14
Talquetamab: Efficacy, AE Management, and Outpatient Strategies and Insights From ASCO 2025
Panelists discuss how extended follow-up from the MonumenTAL-1 trial confirms the durable efficacy and favorable infection profile of talquetamab, while ongoing trials like TALISMAN aim to mitigate its unique toxicity profile.
Bispecifics Targeting GPRC5D and Long-Term Outcomes
Talquetamab, the first approved GPRC5D-targeting bispecific antibody, offers a non-BCMA approach to treating relapsed/refractory multiple myeloma. Long-term data from the MonumenTAL-1 study show sustained responses and a manageable safety profile.
Unlike BCMA-directed agents, talquetamab is associated with unique toxicities such as taste changes, oral ulcers, and dermatologic effects. Despite this, its lower infection risk and durable responses have made it an important addition to the treatment armamentarium.
Extended dosing intervals and proactive toxicity management, including supportive care and schedule modifications, have improved patient compliance and outcomes. Ongoing studies aim to reduce these adverse effects through preventative interventions.
Related Content:
